Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H21N5O4 |
Molecular Weight | 311.3369 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C
InChI
InChIKey=DSFGXPJYDCSWTA-UHFFFAOYSA-N
InChI=1S/C13H21N5O4/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2/h8-9,19-20H,4-7H2,1-3H3
Xanthinol (xanthinol nicotinate) is a xanthine derivative, peripheral vasodilator agent. It exerts it`s pharmacological action by acting as a vasodilator and improves blood flow to brain, arteries, and to the periphery. It increases brain glucose metabolism and thus improves brain ATP levels. It stimulates memory and concentration elevates brain energy levels. Indications for Xanthinol Nicotinate:
1. Peripheral vascular sclerosis
2. Cerebral circulatory disorders
3. Arteriosclerosis
4. Endarteritis obliterans
5. Short term memory disorders
6. Mental flagging
7. Anti ageing memory support
8. Diabetic angiopathy
9. Diabetic gangrene
10. Hyperlipidaemia
11. Intermittent claudication
Side Effects of Xanthinol Nicotinate:
1. Flushing
2. Feeling of warmth
3. Nausea
4. Heart burn
5. Vomiting
6. Itching of skin
For 30 years, Xanthinol nicotinate has been on the market for the treatment of impaired brain function, i.e., organic brain syndromes of various etiologies. Controlled double-blind phase-III clinical trials have shown that xantinol nicotinate is also an effective drug in the treatment of dementia. Xanthinol nicotinate is also helpful in the management of leg ulcers associated with haemoglobinopathies.
Xanthinol was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. The positively charged xanthinol ion is thought to help the transportation of the nicotinic acid into the cell since the later cannot freely diffuse through the cell membrane. The mechanism of action is thought to be related to present influence in the cell metabolism through the nucleotides NAD and NADP. Also, the nicotinic acid is a coenzyme for a lot of proteins involved in tissue respiration (Embden-Meyerhof and citrate cycle). The effect of xanthinol nicotinate causes an increase in glucose metabolism and energy gain.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Complamin Approved UseXanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. |
|||
Primary | Complamin Approved UseXanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. Launch Date1992 |
Sample Use Guides
Typical Dosage for Xanthinol Nicotinate
Oral: 300mg 8th hourly. Increases the dosage up to 600mg 8th hourly if required.
Maximum dose: 1800mg/day.
I.V. or I.M.: 300mg.
Maximum dose: 900mg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26718554
HUASMCs were treated with different concentrations of Xanthinol (xanthinol nicotinate) (0, 2.76, 27.6 or 276 uM), and a 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the inhibition of HUASMC proliferation.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
89795
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB126903
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
9913
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
100000153088
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
DB09092
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
TN1B5910V2
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
4368
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
Xanthinol
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
DTXSID1048255
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY | |||
|
2530-97-4
Created by
admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)